Psychedelics
Exploring the Therapeutic Potential of Psychedelics
We interviewed Ronan Levy, founder and executive chairman of Field Trip Psychedelics, Inc. to find out more about the therapeutic potential of psychedelics and hear about the drugs undergoing clinical investigation.
Your Brain on Psilocybin, With Frederick Streeter Barrett
Fred Barrett is an assistant professor of Psychiatry and Behavioral Sciences at Johns Hopkins University in Baltimore. In this interview, we discuss his work with the active component of magic mushrooms, psilocybin. Fred explains how this compound affects the brain, its potential to combat visceral pain, and its links to so-called mystical experiences.
Ending Psychedelic Myths With Professor David Nutt
Professor David Nutt has never been afraid to stick his head above the parapet on the topic of drugs. His repeated calling-out of the failures of contemporary drug policy has seen him butt heads with academics and politicians alike. In this interview with Professor Nutt, we discuss pot, policy and the potential of psilocybin.
The Neuroscience of Psychedelics: Can LSD Microdosing Make You Happier? With Johannes Ramaekers
How does LSD affects a person's mood? And how can mushrooms could boost creativity? We ask Maastricht University's Professor Johannes Ramaekers, who recently collaborated with the UK-based Beckley foundation to examine the effects of microdosing.
The Neuroscience of Psychedelic Drugs: Octopuses, MDMA and Healing Social Injury
In our latest interview series, we discuss the potential of psychedelics to revolutionize clinical neuroscience with thought leaders in the field. In this first interview of our series exploring the Neuroscience of Psychedelics, we talk to Johns Hopkins Associate Professor Gul Dölen, who has spent years exploring the effects of MDMA on the mammalian (and more recently, cephalopod) brain.
Can Magic Mushrooms Reach the Highs of the Cannabis Industry?
As Denver, Colorado adds magic mushrooms to its growing list of decriminalized substances, is this the start of a whole new legalized drugs wave?
Why Does Ketamine Fight Depression? Finding Answers at BNA 2019
A significant minority of major depressive disorder patients don’t respond to currently available antidepressant medication. A newly approved treatment, based on the "club drug" ketamine, could change that. In a session at the British Neuroscience Association’s Festival of Neuroscience 2019, the potential mechanisms of ketamine’s antidepressant action were put under examination.
Chatting Cannabis With Amanda Feilding, the Countess of Psychedelic Science
Analytical Cannabis speaks to the Queen of Consciousness herself about cannabis, campaigning, and creating a leading foundation for drug science and research.
Microdosers of LSD and Magic Mushrooms are Wiser and More Creative
Researchers just ran the first ever pre-registered scientific study on the microdosing of psychedelics and found some very promising results.
